Alnylam Pharmaceuticals (ALNY) Resumen de Acciones
Alnylam Pharmaceuticals, Inc. descubre, desarrolla, fabrica y comercializa terapias basadas en la interferencia del ácido ribonucleico en Estados Unidos, Europa e internacionalmente. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 5/6 |
| Rendimiento pasado | 3/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en ALNY a partir de nuestros controles de riesgos.
ALNY Community Fair Values
Create NarrativeSee what 70 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Alnylam Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$258.00 |
| Máximo en las últimas 52 semanas | US$495.55 |
| Mínimo de 52 semanas | US$197.81 |
| Beta | 0.30 |
| Cambio en 1 mes | 18.91% |
| Variación en 3 meses | -10.85% |
| Cambio de 1 año | -45.03% |
| Variación en 3 años | 21.90% |
| Variación en 5 años | 37.61% |
| Variación desde la OPV | 4,192.85% |
Noticias y actualizaciones recientes
Actualización de narrativa • Sep 09
ALNY: ATTR Franchise Data And AI Drug Design Will Drive Upside
Alnylam Pharmaceuticals' updated analyst fair value estimate has shifted to $371.35 from $434.72, as analysts factor in tempered Amvuttra growth expectations, revised 2026 TTR revenue guidance, and a slightly higher discount rate, while maintaining a supportive long-term view on the ATTR franchise and RNAi pipeline. Analyst Commentary Recent research on Alnylam Pharmaceuticals gives you a mixed picture.
Actualización de narrativa • Aug 26
ALNY: TTR Guidance Reset And RNAi Pipeline Data Will Shape 2026 Outlook
Alnylam Pharmaceuticals' updated analyst price target of $230, down from $305.63, reflects analysts' shift to slightly higher discount rates, more measured revenue growth assumptions, and a lower future P/E multiple, partly offset by improved profit margin expectations following mixed but generally constructive research commentary across the TTR franchise and RNAi pipeline. Analyst Commentary Recent Street research around Alnylam Pharmaceuticals has turned more mixed, with a series of reduced price targets and tempered expectations around the TTR franchise and Amvuttra commercial ramp.
Actualización de narrativa • Aug 12
ALNY: TTR Franchise And Pipeline Progress Will Support Future Stock Repricing
Analysts have trimmed their fair value estimate for Alnylam Pharmaceuticals, with the price target moving from about $550 to roughly $515. This reflects reduced 2026 TTR and Amvuttra revenue expectations, slightly higher discount rates, and a shift to a richer future P/E multiple, as recent Street research factors in softer near term growth alongside ongoing franchise potential.Recent updates
Actualización de narrativa • Sep 09
ALNY: ATTR Franchise Data And AI Drug Design Will Drive Upside
Alnylam Pharmaceuticals' updated analyst fair value estimate has shifted to $371.35 from $434.72, as analysts factor in tempered Amvuttra growth expectations, revised 2026 TTR revenue guidance, and a slightly higher discount rate, while maintaining a supportive long-term view on the ATTR franchise and RNAi pipeline. Analyst Commentary Recent research on Alnylam Pharmaceuticals gives you a mixed picture.Actualización de narrativa • Aug 26
ALNY: TTR Guidance Reset And RNAi Pipeline Data Will Shape 2026 Outlook
Alnylam Pharmaceuticals' updated analyst price target of $230, down from $305.63, reflects analysts' shift to slightly higher discount rates, more measured revenue growth assumptions, and a lower future P/E multiple, partly offset by improved profit margin expectations following mixed but generally constructive research commentary across the TTR franchise and RNAi pipeline. Analyst Commentary Recent Street research around Alnylam Pharmaceuticals has turned more mixed, with a series of reduced price targets and tempered expectations around the TTR franchise and Amvuttra commercial ramp.Actualización de narrativa • Aug 12
ALNY: TTR Franchise And Pipeline Progress Will Support Future Stock Repricing
Analysts have trimmed their fair value estimate for Alnylam Pharmaceuticals, with the price target moving from about $550 to roughly $515. This reflects reduced 2026 TTR and Amvuttra revenue expectations, slightly higher discount rates, and a shift to a richer future P/E multiple, as recent Street research factors in softer near term growth alongside ongoing franchise potential.Actualización de narrativa • Jul 29
ALNY: ATTR-CM Trial Readouts And Neuroscience Progress Will Shape 2026 Outlook
Alnylam Pharmaceuticals' updated analyst price target has moved modestly lower to $305.63 from $320.21, as analysts refresh models to reflect adjusted expectations for the TTR franchise and evolving competitive signals from recent ATTR-CM trial outcomes. Analyst Commentary Recent research updates on Alnylam Pharmaceuticals reflect a mixed set of views as analysts adjust models for the TTR franchise, Amvuttra, and the longer term outlook for nucresiran in light of evolving ATTR-CM data and competition.Seeking Alpha • Jul 16
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns
Summary I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pullback as an overreaction. AMVUTTRA now holds a near-term commercial monopoly in TTR silencing, with strong clinical data and $890 million in Q1 2026 revenue. ALNY's robust cash position ($3.0 billion) and GAAP profitability materially reduce investment risk and support pipeline development. Key risks include AMVUTTRA's market penetration, payer dynamics, and phase 3 outcomes for nucresiran, but current valuation discounts near-term strengths. Read the full article on Seeking AlphaActualización de narrativa • Jul 14
ALNY: ATTR-CM Competitive Shift And AI Expansion Will Drive Future Upside
Analysts have modestly increased their fair value estimate for Alnylam Pharmaceuticals, with the price target moving from about $310.31 to $320.21, as they update models to reflect shifting expectations for long term revenue growth, profit margins, and future P/E assumptions following recent mixed research commentary on the ATTR-CM franchise. Analyst Commentary Recent research on Alnylam Pharmaceuticals reflects a split view, with some firms lifting price targets and others trimming them as they reassess assumptions for the ATTR-CM opportunity, competitive pressures, and execution risks around upcoming data and launches.Actualización de narrativa • Jun 30
ALNY: Cardiomyopathy Expansion And AI Partnerships Will Drive Long Term Upside
Alnylam Pharmaceuticals' analyst-derived fair value estimate has been revised from $491.92 to $434.72 as analysts temper revenue growth and margin assumptions, following mixed adjustments to price targets and updated views on the Amvuttra launch and TTR franchise trajectory. Analyst Commentary Recent commentary on Alnylam Pharmaceuticals shows a mix of optimism around the long term potential of the TTR franchise and more cautious views on execution and valuation in the near term.Actualización de narrativa • Jun 16
ALNY: TTR Franchise Execution And 2030 Plan Will Support Stock Repricing
The analyst price target for Alnylam Pharmaceuticals has been adjusted to $550. This move reflects updated views on fair value, growth assumptions, and profitability, while aligning with recent Street commentary that highlights both the pullback in the stock and ongoing expectations around Amvuttra's launch and competitive pressures.Actualización de narrativa • Jun 02
ALNY: Fair View Balances ATTR-CM Data Progress With Competition And Pipeline Execution
Alnylam Pharmaceuticals' analyst fair value estimate has edged down by about $1 to $310.31, as analysts balance slightly softer modeled revenue growth and a marginally higher discount rate with a stronger profit margin outlook and ongoing support from recent price target moves and coverage initiations. Analyst Commentary Street research on Alnylam Pharmaceuticals currently reflects a mix of optimism on the drug pipeline and caution on how much of that potential is already reflected in the share price.Actualización de narrativa • May 11
ALNY: Fair View Weighs TTR Execution Risks Against Cardiovascular Pipeline Progress
Analysts have nudged Alnylam Pharmaceuticals' fair value estimate to $311.72 from $310.00, reflecting updated assumptions for slightly lower revenue growth and profit margins, as well as a higher future P/E multiple based on recent shifts in price targets and commentary across the Street. Analyst Commentary Recent research has highlighted a mixed backdrop for Alnylam Pharmaceuticals, with some firms revising targets higher on product execution while others voice concern that the stock already reflects optimistic outcomes.Actualización de narrativa • Apr 20
ALNY: Fair View Balances TTR Execution Uncertainty With Cardiovascular Pipeline Progress
Analysts have trimmed the Alnylam Pharmaceuticals fair value estimate to $310 from $322.59, reflecting a series of reduced price targets and higher discount-rate assumptions, even as revenue growth expectations remain higher and long term profit margins and future P/E forecasts are more moderate. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed setup where confidence in the RNAi platform and the Amvuttra franchise is balanced against tighter valuation views and more conservative long term assumptions.Actualización de narrativa • Apr 06
ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' analyst price targets have been reset across the Street, with several cuts from firms now clustering in a roughly $249 to $570 range, as analysts balance concerns that shares are "priced to perfection" and that long term expectations may be too rich, against continued confidence in the RNAi platform and the strong Amvuttra launch in TTR and ATTR-CM. Analyst Commentary Recent research updates show a split tape on Alnylam, with some firms trimming targets and others leaning into the story as Amvuttra execution and RNAi platform confidence remain central themes.Actualización de narrativa • Mar 23
ALNY: TTR Franchise Momentum Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' updated analyst price targets show a wide reset across the Street, with cuts from firms now clustered around the $249 to $570 range. Analysts are balancing strong Amvuttra momentum and the RNAi platform's potential with concerns that the shares had been priced for very optimistic growth and competition assumptions.Actualización de narrativa • Mar 07
ALNY: TTR Execution Will Support Confidence In 2026 Revenue Outlook
Analysts have trimmed their fair value estimate for Alnylam Pharmaceuticals by $14 to $566, reflecting higher discount rates and more conservative assumptions for revenue growth and profit margins, even as they continue to highlight strong Amvuttra traction and supportive 2026 guidance in recent research. Analyst Commentary Recent research paints a mixed picture on valuation, but there is still a clear cluster of optimistic views around Alnylam's execution, especially in its TTR franchise and Amvuttra rollout.Actualización de narrativa • Feb 21
ALNY: Fair View Weighs TTR Franchise Guidance Against Launch Execution Risks
The updated analyst price target for Alnylam Pharmaceuticals has decreased by about $45 per share, as analysts refresh their models with slightly softer revenue growth assumptions, a modestly higher long-term profit margin, and a reduced future P/E multiple. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed backdrop, with several firms revisiting their models following Q4 results, preannounced revenue figures, and updated 2026 guidance.Actualización de narrativa • Feb 06
ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Guidance
Analysts have trimmed their average price targets on Alnylam Pharmaceuticals by roughly $35 to $70, largely reflecting updated views on Amvuttra revenue trajectories, competitive pressures in ATTR-CM and recent guidance that, while still supported by continued TTR franchise momentum, has prompted more measured growth assumptions. Analyst Commentary Recent research updates show a mixed but generally constructive tone on Alnylam, with several bullish analysts pointing to execution on the TTR franchise, early Amvuttra traction in ATTR-CM and management guidance as key supports for valuation.Actualización de narrativa • Jan 23
ALNY: TTR Franchise Momentum Will Drive 2026 Revenue Guidance Confidence
Narrative Update: Alnylam Pharmaceuticals Price Target Revision The analyst price target for Alnylam Pharmaceuticals has been raised by $10 to $580, as analysts weigh mixed target changes across the Street alongside company guidance that highlights ongoing momentum in the TTR franchise and a positive outlook for revenue driven by Amvuttra. Analyst Commentary Recent Street research around Alnylam Pharmaceuticals has been active, with several price target revisions and fresh commentary following the company’s Q3 results, preliminary Q4 figures, and updated 2025 and 2026 revenue guidance.Actualización de narrativa • Jan 09
ALNY: Fair View Balances TTR Guidance Upside And Launch Deceleration Risk
Alnylam Pharmaceuticals' analyst fair value estimate has been raised from about $259.89 to about $368.22, as analysts factor in stronger modeled revenue growth, higher projected profitability, and a reset to more moderate future P/E expectations following recent research updates around Amvuttra uptake and revised TTR guidance. Analyst Commentary Recent research on Alnylam highlights a mixed backdrop.Actualización de narrativa • Dec 26
ALNY: Cardiomyopathy Launch Will Drive Future Upside Despite Growing Competitive Pressures
Analysts have modestly lifted their price target for Alnylam Pharmaceuticals, reflecting stronger Amvuttra driven TTR revenue expectations and a series of Street target increases into the mid 400s to mid 500s, even as they highlight a more balanced risk and the potential for range bound trading into 2026. Analyst Commentary Recent Street research reflects a constructive but increasingly balanced view on Alnylam, with multiple firms lifting price targets into the mid 400s to mid 500s on the back of stronger Amvuttra traction and higher TTR revenue expectations, while also flagging valuation and competitive considerations that could cap upside.Actualización de narrativa • Dec 12
ALNY: Cardiomyopathy Launch Will Drive Future Momentum Despite Intensifying Competition
Alnylam Pharmaceuticals’ fair value estimate has nudged higher to approximately $493 from about $489 as analysts lift price targets into the mid to high $400s, citing stronger than expected Amvuttra driven TTR revenue growth and a still rich but increasingly supported long term earnings profile. Analyst Commentary Street research remains broadly constructive on Alnylam, with multiple firms lifting price targets into the mid to high $400s and several pushing above $500.Actualización de narrativa • Nov 27
ALNY: Future Momentum In Cardiomyopathy Will Meet Rising Competition And Pricing Pressures
The analyst price target for Alnylam Pharmaceuticals has increased by approximately $9 to $489, as analysts cite strong Amvuttra sales, raised revenue guidance, and resilient commercial momentum as key factors supporting a more optimistic outlook. Analyst Commentary Analysts have provided a range of perspectives following Alnylam Pharmaceuticals’ recent performance, with several raising their price targets and highlighting both catalysts and areas of caution for the company’s outlook.Actualización de narrativa • Nov 12
ALNY: Momentum In Cardiomyopathy Segment Will Face Intensifying Competitive Risks Ahead
Alnylam Pharmaceuticals’ fair value estimate has increased from $467.94 to $480.17. This change reflects analysts' optimism about robust Amvuttra sales, raised revenue guidance, and an improved profit margin outlook.Actualización de narrativa • Oct 29
Cardiomyopathy Launches And Pipeline Expansion Will Sustain Momentum Into 2025
Analysts have increased their price target for Alnylam Pharmaceuticals by approximately $16, citing stronger than expected product launches and continued commercial momentum. Analyst Commentary Following a series of upward price target revisions, Wall Street analysts remain broadly upbeat about Alnylam Pharmaceuticals’ near-term commercial performance and long-term prospects.Actualización de narrativa • Oct 14
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals' analyst price targets have recently moved higher, with analysts citing stronger commercial performance of Amvuttra and encouraging data from pipeline assets as drivers behind the upward revisions. The cited targets have climbed by as much as $55 to $583 per share.Actualización de narrativa • Sep 23
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals’ price target was raised to $447.15 as analysts cited accelerating Amvuttra sales, positive clinical progress, robust financial execution, and increased revenue forecasts, reflecting growing confidence in the company’s commercial momentum and pipeline. Analyst Commentary Strong commercial momentum for Amvuttra, particularly in ATTR-CM, with sales trends and script data consistently exceeding expectations.Actualización de narrativa • Sep 08
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam’s modestly lower consensus price target to $421.20 reflects both strong near-term Amvuttra uptake in ATTR-CM and positive revenue outlook, tempered by mixed KARDIA-3 data for zilebesiran and resulting slight valuation adjustment. Analyst Commentary Bullish analysts cited strong commercial performance and encouraging uptake for Amvuttra, particularly following its approval and launch in ATTR-CM (transthyretin amyloid cardiomyopathy), as a key driver for raising price targets.Seeking Alpha • Mar 21
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Summary Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like zilebesiran, supports long-term growth and will reduce its heavy near-term reliance on the TTR franchise. Amvuttra is likely to see strong initial adoption in ATTR-CM patients who've progressed on stabilizers, but greater first-line use and switchovers could drive the upside. Alnylam's proven R&D engine and above-average success ratio make it a compelling long-term biotech investment despite arguably modest immediate upside. Read the full article on Seeking AlphaRentabilidad de los accionistas
| ALNY | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -3.5% | -4.4% | -0.2% |
| 1Y | -45.0% | 39.9% | 14.8% |
Rentabilidad vs. Industria: Los resultados de ALNY fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 39.9% el año pasado.
Rentabilidad vs. Mercado: ALNY obtuvo unos resultados inferiores a los del mercado US, que fueron del 14.8% el año pasado.
Volatilidad de los precios
| ALNY volatility | |
|---|---|
| ALNY Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: ALNY no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ALNY (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2002 | 2,500 | Yvonne Greenstreet | www.alnylam.com |
Alnylam Pharmaceuticals, Inc. descubre, desarrolla, fabrica y comercializa terapias basadas en la interferencia del ácido ribonucleico en Estados Unidos, Europa e internacionalmente. La empresa ofrece ONPATTRO para la amiloidosis hereditaria mediada por transtiretina (hATTR); AMVUTTRA para la amiloidosis ATTR y hATTR; Leqvio para la hipercolesterolemia; Qfitlia para la hemofilia A o B; GIVLAARI para la porfiria hepática aguda; y OXLUMO para la hiperoxaluria primaria de tipo 1. También desarrolla una serie de productos en fase 3 de ensayo, como Nucresiran para la amiloidosis ATTR; Zilebesiran para la hipertensión; Cemdisiran para la miastenia gravis, la hemoglobinuria paroxística nocturna y la atrofia geográfica; y Elebsiran para las infecciones por el virus de la hepatitis D. Además, la empresa está desarrollando varios productos en fase 2 de ensayo, entre ellos Rapirosiran para la esteatohepatitis asociada a disfunción metabólica; ALN-ANG3 para la enfermedad renal diabética; ALN-4324 para la diabetes mellitus tipo 2; Mivelsiran para la angiopatía amiloide cerebral, así como en fase 1 de ensayo para la enfermedad de Alzheimer; y ALN-6400 para trastornos hemorrágicos.
Resumen de fundamentos de Alnylam Pharmaceuticals, Inc.
| Estadísticas fundamentales de ALNY | |
|---|---|
| Capitalización bursátil | US$34.80b |
| Beneficios(TTM) | US$774.71m |
| Ingresos (TTM) | US$4.80b |
44.6x
Ratio precio-beneficio (PE)7.2x
Ratio precio-ventas (PS)¿Está ALNY sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ALNY | |
|---|---|
| Ingresos | US$4.80b |
| Coste de los ingresos | US$977.45m |
| Beneficio bruto | US$3.83b |
| Otros gastos | US$3.05b |
| Beneficios | US$774.71m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 5.79 |
| Margen bruto | 79.65% |
| Margen de beneficio neto | 16.13% |
| Ratio deuda/patrimonio | 201.7% |
¿Cómo se ha desempeñado ALNY a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/09 13:10 |
| Precio de las acciones al final del día | 2026/09/09 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Alnylam Pharmaceuticals, Inc. está cubierta por 56 analistas. 26 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |
| Emily Bodnar | Berenberg |